Erika Richtig - Dissemin

Language
Login

All papers authored by Erika Richtig

This paper is made freely available by the publisher.

2022 Paolo A. Ascierto

ORCID

, Mario Mandalà

ORCID

, Pier Francesso Ferrucci

ORCID

, Massimo Guidoboni

ORCID

, Piotr Rutkowski

ORCID

, Virginia Ferraresi, Ana Arance

ORCID

, Michele Guida, Evaristo Maiello

ORCID

ORCID

, Erika Richtig

ORCID

, Maria Teresa Fierro, Celeste Lebbè

ORCID

, Hildur Helgadottir, Paola Queirolo and 15 other authors

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

Download from doi.org

This paper is made freely available by the publisher.

2021 Silke Schrom, Thomas Hebesberger

ORCID

, Stefanie Angela Wallner, Ines Anders, Erika Richtig

ORCID

, Waltraud Brandl, Birgit Hirschmugl, Mariangela Garofalo

ORCID

, Claudia Bernecker

ORCID

, Peter Schlenke

ORCID

, Karl Kashofer, Christian Wadsack

ORCID

, Ariane Aigelsreiter, Ellen Heitzer

ORCID

, Sabrina Riedl and 4 other authors

MUG Mel3 Cell Lines Reflect Heterogeneity in Melanoma and Represent a Robust Model for Melanoma in Pregnancy

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

2017 Teresa M. Petrella, Caroline Robert, Erika Richtig

ORCID

, Wilson H. Miller, Giuseppe V. Masucci

ORCID

, Euan Walpole, Celeste Lebbe, Neil Steven, Mark R. Middleton, Darcy Hille, Wei Zhou, Nageatte Ibrahim, Jonathan Cebon

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma

Upload

Missing publications? Search for publications with a matching author name.